---
title: "M Stanley Cuts JD HEALTH  TP to HKD45, Maintains Equalweight Rating"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/306088316.md"
description: "Morgan Stanley lowered JD Health's target price to HKD45 from HKD49.6 and cut EPS forecasts for 2026-2028 due to slower growth in nutritional supplements and margin pressures, while maintaining an 'Equalweight' rating. The broker cited accelerating organic growth slowdown, softer macro conditions, and intensifying competition as key headwinds, despite long-term benefits from healthcare e-commerce expansion and parent company support."
datetime: "2026-11-19T08:46:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/306088316.md)
  - [en](https://longbridge.com/en/news/306088316.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/306088316.md)
generator: "portal-rs"
---

# M Stanley Cuts JD HEALTH  TP to HKD45, Maintains Equalweight Rating

Morgan Stanley issued a research report stating that after updating its model following JD HEALTH (06618.HK) -2.440 (-6.999%) Short selling $304.93M; Ratio 32.620% 's third-quarter results, it lowered its EPS forecasts for 2026 to 2028 by 1%, 2% and 9%, respectively, reflecting slower growth in nutritional supplements and corresponding reductions in margin assumptions. The broker rolled forward its DCF model to start from 2027 and cut the TP from HKD49.6 to HKD45, while maintaining an "Equalweight" rating.

The broker said JD HEALTH (06618.HK) -2.440 (-6.999%) Short selling $304.93M; Ratio 32.620% is China's leading healthcare e-commerce platform by direct sales scale and is expected to benefit in the long run from the online expansion potential of healthcare products, particularly pharmaceuticals. The company also receives support from its parent company in traffic guidance, platform business revenue sharing and logistics. However, accelerating slowdown in organic growth, softer macro conditions, intensifying competition among e-commerce peers and other disruptive internet healthcare models continue to pose pressure. Short-term margin growth is also slowing due to upfront investments in new businesses.

Under its base-case scenario, the broker assumes revenue CAGR of about 10% for 2026 to 2028, with margins remaining broadly stable.(da/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-11-19 16:25.)

### Related Stocks

- [06618.HK](https://longbridge.com/en/quote/06618.HK.md)
- [86618.HK](https://longbridge.com/en/quote/86618.HK.md)
- [MS.US](https://longbridge.com/en/quote/MS.US.md)

## Related News & Research

- [JD Health Trustee Purchases Shares for Post-IPO Award Scheme](https://longbridge.com/en/news/306036144.md)
- [JD Health Shareholders Approve All Resolutions at 2026 AGM](https://longbridge.com/en/news/291152034.md)
- [The bank of Nvidia is getting more ‘disciplined,’ selective](https://longbridge.com/en/news/306148745.md)
- [PRESS DIGEST-New York Times business news - November 20](https://longbridge.com/en/news/306242079.md)
- [NetEase Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into NetEase (NTES)](https://longbridge.com/en/news/306200520.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**